Valuation: Increased to $64–111mWe increase our indicative valuation range to $64–111m or $10.31–17.82 per ADR (vs $63–105m, $10.51–17.57 per ADR), under either post-Phase III approval or accelerated approval scenarios for GDC-0084. We have rolled forward our model and have made adjustment for the sale of the Noxopharm shareholding for $1.8m (vs our previous valuation of $2.7m). We estimate that cash of $4.1m at 31 December 2018 plus the Noxopharm sale proceeds will fund activity into H219, by which time preliminary data from the GDC-0084 Phase IIa are expected to have read out. We estimate that Kazia will need additional funds in the order of $11-15m to fully fund the GDC-0084 Phase IIb study.
IMO full increased valuation of KZA $64m - $111m based on post phase 111 approval or accelerated approval of GDC0084 - which has to be years away from now at best
imo
$23m market cap at present is far from cheap based on the valuations above - hence no conspiracy or manipulation theories or Hopper selling tiny 150k shares in one month
The licence deal - agreements imo is the key here
Was this a good deal for KZA based on above valuations. etc.....
- Forums
- ASX - By Stock
- Selling
Valuation: Increased to $64–111mWe increase our indicative...
-
-
- There are more pages in this discussion • 144 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add KZA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
CCO
THE CALMER CO INTERNATIONAL LIMITED
Anthony Noble, MD & CEO
Anthony Noble
MD & CEO
Previous Video
Next Video
SPONSORED BY The Market Online